Flavia Fraschetti

Dr. Flavia Fraschetti


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AFAlessandro Frati
Alessandro Frati
DCDaniela Cerretani
Daniela Cerretani
AFAnna Ida Fiaschi
Anna Ida Fiaschi
PFPaola Frati
Paola Frati
VGVittorio Gatto
Vittorio Gatto
VFVittorio Fineschi
Vittorio Fineschi
Traumatic brain injury (TBI) is one of the world’s leading causes of morbidity and mortality among young individuals. TBI applies powerful rotational and translational forces to the brain parenchyma, which results in a traumatic diffuse axonal injury (DAI) responsible for brain swelling and neuronal death. Following TBI, axonal degeneration has been identified as a progressive process that starts with disrupted axonal transport causing axonal swelling, followed by secondary axonal disconnection and Wallerian degeneration. These modifications in the axonal cytoskeleton interrupt the axoplasmic transport mechanisms, causing the gradual gathering of transport products so as to generate axonal swellings and modifications in neuronal homeostasis. Oxidative stress with consequent impairment of endogenous antioxidant defense mechanisms plays a significant role in the secondary events leading to neuronal death. Studies support the role of an altered axonal calcium homeostasis as a mechanism in the secondary damage of axon, and suggest that calcium channel blocker can alleviate the secondary damage, as well as other mechanisms implied in the secondary injury, and could be targeted as a candidate for therapeutic approaches. Reactive oxygen species (ROS)-mediated axonal degeneration is mainly caused by extracellular Ca2+. Increases in the defense mechanisms through the use of exogenous antioxidants may be neuroprotective, particularly if they are given within the neuroprotective time window. A promising potential therapeutic target for DAI is to directly address mitochondria-related injury or to modulate energetic axonal energy failure.

1 July 2017 in World Neurosurgery
Verified
Journal Article
Closed access
ARAntonino Raco
Antonino Raco
APAlessandro Pesce
Alessandro Pesce
FFFlavia Fraschetti
Flavia Fraschetti
AFAlessandro Frati
Alessandro Frati
GDGiancarlo D’aNdrea
Giancarlo D’aNdrea
MAMichele Acqui
Michele Acqui

1 April 2018 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
AFAlessandro Frati
Alessandro Frati
APAlessandro Pesce
Alessandro Pesce
GDGiancarlo D'Andrea
Giancarlo D'Andrea
FFFlavia Fraschetti
Flavia Fraschetti
MSMaurizio Salvati
Maurizio Salvati
ARAntonino Raco
Antonino Raco

27 May 2019 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
PFPaolo Frassanito
Paolo Frassanito
FBFederico Bianchi
Federico Bianchi
VSVito Stifano
Vito Stifano
FFFlavia Fraschetti
Flavia Fraschetti
Luca MassimiLuca Massimi
Luca Massimi
MCMassimo Caldarelli
Massimo Caldarelli

3 June 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AAAmer A. Alomari
Amer A. Alomari
SESadeen Eid
Sadeen Eid
FFFlavia Fraschetti
Flavia Fraschetti
SMSilvia Michelini
Silvia Michelini
LMLuciano Mastronardi
Luciano Mastronardi
Background: Vestibular schwannoma (VS), also known as acoustic neuroma, is a benign, well-encapsulated, and slow-growing tumor that originates from Schwann cells, which form the myelin sheath around the vestibulocochlear nerve (VIII cranial nerve). The surgical treatment of this condition presents a challenging task for surgeons, as the tumor’s location and size make it difficult to remove without causing damage to the surrounding structures. In recent years, fluorescein sodium (FS) has been proposed as a tool to enhance surgical outcomes in VS surgery. This essay will provide an analytical comparison of the use of FS in VS surgery, evaluating its benefits and limitations and comparing surgical outcomes with and without FS-assisted surgery. Methods: In a retrospective study conducted at San Filippo Neri Hospital, we examined VS cases that were operated on between January 2017 and December 2023. The patients were divided into two groups: group A, which consisted of patients who underwent surgery without the use of FS until January 2020 (102 cases), and group B, which included patients who underwent surgery with FS after January 2020 (55 cases). All operations were performed using the retrosigmoid approach, and tumor size was classified according to the Koos, et al. classification system. The extent of surgical removal was evaluated using both the intraoperative surgeon’s opinion and postoperative MRI imaging. Preoperatively and postoperatively, facial nerve function and hearing were assessed. In group B, FS was used to assist the surgical procedures, which were performed using a surgical microscope equipped with an integrated fluorescein filter. Postoperative clinical and MRI controls were performed at six months and annually, with no patients lost to follow-up. Results: This study investigated the impact of intraoperative fluorescein exposure on tumor resection and clinical outcomes in patients with VS. The study found a statistically significant difference in the tumor resection rates between patients who received fluorescein intraoperatively (p = 0.037). Further analyses using the Koos classification system revealed a significant effect of fluorescein exposure, particularly in the Koos 3 subgroup (p = 0.001). Notably, no significant differences were observed in hearing loss or facial nerve function between the two groups. A Spearman correlation analysis revealed a positive correlation between tumor size and Koos, age, and size, but no significant correlation was found between facial nerve function tests. Conclusions: FS-assisted surgery for VS may potentially enhance tumor resection, allowing for more comprehensive tumor removal.

20 October 2023 in Surgical Neurology International
Verified
Journal Article
Open access
SMSalvatore Marrone
Salvatore Marrone
JSJulio Alberto Andres Sanz
Julio Alberto Andres Sanz
GCGuglielmo Cacciotti
Guglielmo Cacciotti
ACAlberto Campione
Alberto Campione
FBFabio Boccacci
Fabio Boccacci
LMLuciano Mastronardi
Luciano Mastronardi
Background: Cervical schwannoma is a rare neoplasm that usually occurs like a nondolent lateral neck mass but when growing and symptomatic requires radical excision. Sodium fluorescein (SF) is a dye that is uptake by schwannomas, which makes it amenable for its use in the resection of difficult or recurrent cases. Methods: We describe the case of a patient presenting with a recurrence of a vagus nerve schwannoma in the cervical region and the step-by-step technique for its complete microsurgical exeresis helped by the use of SF dye. Results: We achieved a complete microsurgical exeresis, despite the presence of exuberant perilesional fibrosis, by exploiting the ability of SF to stain the schwannoma and nearby tissues. That happens due to altered vascular permeability, allowing us to better differentiate the lesion boundaries and reactive scar tissue under microscope visualization (YELLOW 560 nm filter). Conclusion: Recurrent cervical schwannoma might represent a surgical challenge due to its relation to the nerve, main cervical vessels, and the scar tissue encompassing the lesion. Although SF can cross both blood–brain and blood–tumor barriers, the impregnation of neoplastic tissue is still greater than that of nonneoplastic peripheric tissues. Such behavior may facilitate a safer removal of this kind of lesion while respecting contiguous anatomical structures.